Jeff Vacirca
About Jeff Vacirca
Jeff Vacirca is a co-founder and director with extensive experience in oncology and healthcare. He currently holds multiple board positions and has been involved in various initiatives to support cancer patients and research.
Work at OneOncology
Jeff Vacirca serves as Co-Founder and Director at OneOncology, a position he has held since 2019. He is also a Board Member at OneOncology, having joined in 2018. His role involves overseeing strategic initiatives and contributing to the organization’s mission of enhancing cancer care. He is actively involved in the Compensation Committee, where he helps guide compensation strategies for the organization.
Board Memberships and Leadership Roles
Vacirca holds several board positions across various organizations. He has been a member of the Board of Directors at PatientPoint® since 2023 and at Assertio since 2023. Additionally, he has served on the Board of Directors for Annexus Health since 2021. His leadership extends to the American Red Cross, where he has been a board member since 2017, and he has also served as Immediate Past President of the Community Oncology Alliance since 2017.
Education and Expertise
Jeff Vacirca has extensive experience in oncology and healthcare management. He co-founded the National Translational Research Group and serves as its president, reflecting his commitment to advancing cancer research. He is also the medical director for Oncology Network Development at Mt. Sinai Health Network, where he oversees initiatives aimed at improving oncology services.
Achievements in Cancer Advocacy
Vacirca has made significant contributions to cancer advocacy through various initiatives. He founded the New York Cancer Foundation in 2014 to provide financial assistance to cancer patients undergoing treatment. He also formed the Conquering Cancer PAC, aimed at advocating for cancer patients and ensuring their access to care. His involvement in early funding for companies like Cedar, Thyme Care, and Sherpa Health highlights his commitment to innovation in cancer care.
Previous Roles and Contributions
Before his current roles, Jeff Vacirca served on the board of Spectrum Pharmaceuticals and was part of the contracting advisory board for the International Oncology Network for nearly 15 years. He co-founded Odonate Therapeutics in 2016, contributing to the development of therapies for cancer treatment. Additionally, he has been a Medical Board Advisor at Caris Life Sciences since 2014, focusing on advancements in precision medicine.